article · Alzheimer s & Dementia
Abstract Background Poor cardiovascular health is a risk factor for cognitive decline and dementia, including Alzheimer's disease (AD). Development of ancestry‐informed blood‐based biomarkers for the small vessel diseases of the brain that contribute to vascular cognitive impairment across multiple populations is critical to identify individuals at risk. To begin addressing this, we examined the associations of blood‐based biomarkers of endothelial function and vascular disease with AD biomarkers and genetic ancestry in 1,534 admixed Hispanic and African American individuals from the PRADI and READD‐ADSP. Methods Biomarkers of endothelial function and vascular disease included VEGF, PlGF, bFGF, VCAM‐1, ICAM‐1, HbA1C, and plasma lipid levels. AD biomarkers included Aβ40, Aβ42, and p ‐tau181. Adjusting for age and sex as covariates, linear regressions were modeled separately predicting the three AD biomarkers by all 7 cardiovascular biomarkers, as well as degree of African ancestry. Additional regression models were run predicting each AD biomarker by each cardiovascular biomarker individually while controlling for age and sex and examining the interaction between the endothelial/vascular biomarker and African ancestry. Results Aβ40 is associated with VEGF, PlGF, VCAM‐1, HbA1c, and African ancestry (Table 1); Aβ42 is associated with VEGF, PlGF, HbA1c, and African ancestry (Table 2); and p ‐tau181 is associated with VEGF and African ancestry (Table 3). In addition, an interaction between cardiovascular biomarker and degree of African ancestry was observed for bFGF (β = 0.83, P = .03) while predicting Aβ40, ICAM‐1 (β = ‐0.006, P = .04) while predicting Aβ42, and VEGF (β = 0.03, P = .02) and total cholesterol (β = ‐0.11, P = .002) while predicting p ‐tau181. Conclusions Levels of VEGF, PlGF, VCAM‐1, and HbA1c predict levels of AD biomarkers in admixed individuals, and these associations are influenced by degree of African ancestry. While these findings need additional validation, they support the notion that endothelial disease contributes to cognitive impairment and that the assessed biomarkers may be valuable biomarkers for clinical settings. These results underscore the importance of biomarker research and validation in individuals from multiple populations.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1002/alz70856_106480
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.